[1] Ovciarikova J, Lemgruber L, Stilger KL, et al. Mitochondrial behaviour throughout the lytic cycle of Toxoplasma gondii[J]. Sci Rep, 2017, 7:42746. doi:10.1038/srep42746. [2] Salazar Gonzalez RM, Shehata H, O'Connell MJ, et al. Toxoplasma gondii-derived profilin triggers human toll-like receptor 5-dependent cytokine production[J]. J Innate Immun, 2014, 6(5):685-694. [3] Ge Y, Chen J, Qiu X, et al. Natural killer cell intrinsic toll-like receptor MyD88 signaling contributes to IL-12-dependent IFN-γ production by mice during infection with Toxoplasma gondii[J]. Int J Parasitol, 2014, 44(7):475-484. [4] Krishnamurthy S, Konstantinou EK, Young LH, et al. The human immune response to Toxoplasma:Autophagy versus cell death[J]. PLoS Pathog, 2017, 13(3):e1006176. [5] Tosh KW, Mittereder L, Bonne-Annee S, et al. The IL-12 response of primary human dendritic cells and monocytes to toxoplasma gondii is stimulated by phagocytosis of live parasites rather than host cell invasion[J]. J Immunol, 2016, 196(1):345-356. [6] Che FY, Madrid-Aliste C, Burd B, et al. Comprehensive proteomic analysis of membrane proteins in Toxoplasma gondii[J]. Mol Cell Proteomics, 2011,10(1):1-14. [7] Alam A, Bhatnagar RK, Relan U, et al. Proteolytic activity of Plasmodium falciparum subtilisin-like protease 3 on parasite profilin, a multifunctional protein[J]. Mol Biochem Parasitol, 2013, 191(2):58-62. [8] Koblansky AA, Jankovic D, Oh H, et al. Recognition of Profilin by Toll-like Receptor 12 is Critical for Host Resistance to Toxoplasma gondii[J]. Immunity, 2013, 38(1):119-130. [9] Raetz M, Kibardin A, Sturge CR, et al. Cooperation of TLR12 and TLR11 in the IRF8-dependent IL-12 response to Toxoplasma gondii profilin[J]. J Immunol, 2013,191(9):4818-4827. [10] Tanaka S, Kuroda Y, Ihara F, et al. Vaccination with profilin encapsulated in oligomannose-coated liposomes induces significant protective immunity against Toxoplasma gondii[J].Vaccine, 2014,32(16):1781-1785. [11] Kramer K, Shields NJ, Poppe V, et al. Intracellular cleavable CpG oligodeoxynucleotide-antigen conjugate enhances anti-tumor immunity[J]. Mol Ther, 2017, 25(1):62-70. [12] Hanagata N. CpG oligodeoxynucleotide nanomedicines for the prophylaxis or treatment of cancers, infectious diseases, and allergies[J].Int J Nanomedicine, 2017, 12:515-531. [13] Srivastava AK, Yolcu ES, Dinc G, et al. SA-4-1BBL/MPL as a novel immune adjuvant platform to combat cancer[J].Oncoimmunology,2016, 5(1):e1064580. [14] Pyo KH, Lee YW, Lim SM, et al. Immune adjuvant effect of a Toxoplasma gondii profilin-like protein in autologous whole-tumor-cell vaccination in mice[J]. Oncotarget, 2016,7(45):74107-74119. [15] Halonen SK, Weiss LM. Toxoplasmosis[J].Handb Clin Neurol, 2013,114:125-145. [16] Yarovinsky F. Innate immunity to Toxoplasma gondii infection[J]. Nat Rev Immunol, 2014, 14(2):109-121. [17] Engel MA, Neurath MF. Anticancer properties of the IL-12 family--focus on colorectal cancer[J]. Curr Med Chem, 2010, 17(29):3303-3308. [18] Rankin EB, Yu D, Jiang J, et al. An essential role of Th1 responses and interferon gamma in infection-mediated suppression of neoplastic growth[J]. Cancer Biol Ther, 2003, 2(6):687-693. |